We have previously shown that radiation increases HIF-1 activity in tumors, causing significant radioprotection of the tumor vasculature. The impact that HIF-1 activation has on overall tumor radiosensitivity, however, is unknown. We reveal here that HIF-1 plays an important role in determining tumor radioresponsiveness through regulating four distinct processes. By promoting ATP metabolism, proliferation, and p53 activation, HIF-1 has a radiosensitizing effect on tumors. Through stimulating endothelial cell survival, HIF-1 promotes tumor radioresistance. As a result, the net effect of HIF-1 blockade on tumor radioresponsiveness is highly dependent on treatment sequencing, with "radiation first" strategies being significantly more effective than the alternative. These data provide a strong rationale for pursuing sequence-specific combinations of HIF-1 blockade and conventional therapeutics.
Introduction
. It also plays a very important role in modulating treatment responsiveness. High tumor HIF-1 Radiation plays an important role in the treatment of cancer.
activity is an independent predictor of poor prognosis after raAlthough modern technology has made it an effective tool, diotherapy (Aebersold et al., 2001; Koukourakis et al., 2002) . dose-limiting normal tissue toxicities and radioresistant tumors For this reason, the interplay between radiotherapy and HIF-1 still lead to life-threatening radiation treatment failures. In order warrants detailed investigation. to improve its therapeutic ratio, there has been much interest
We recently found that ionizing radiation significantly upreguin augmenting the effect of radiation on tumors by combining lates HIF-1 activity in tumors (Moeller et al., 2004) . Radiation it with molecularly targeted tumor therapeutics (Camphausen causes tumor oxygenation to increase, causing, in turn, both and Tofilon, 2004). As this approach is beginning to show the accumulation of tumor-reactive oxygen/nitrogen species promise, there is a continued need for the discovery of novel and the depolymerization of stress granules. These two events critical molecular targets whose inhibition might enhance ralead to increased expression of HIF-1 and its target downstream diotherapeutic response.
genes. As a result, the increased expression of HIF-1-regulated Hypoxia-inducible factor-1 (HIF-1) is an excellent potential cytokines delivers survival signals to tumor endothelium, recandidate for targeted inhibition to improve radiation outcome.
sulting in tumor radioresistance through vascular radioproIt is a nuclear transcription factor whose activity is promoted tection. by hypoxia (Wang and Semenza, 1993) , oxidative stress (ChanThis prior work strongly supports the claim that HIF-1 is a del et al., 1998), and oncogenes (Laughner et al., 2001 ; Zundel rational target for tumor radiosensitization. However, the comet al., 2000); as such, it is commonly upregulated in tumors plex roles of this protein require that caution be taken before (Zhong et al., 1999) . It influences tumor biology by regulating moving this strategy forward. Many of the phenotypes regu-60+ genes that contribute to crucial behaviors such as angiolated by HIF-1 activity are known modifiers of cellular radiosengenesis (Maxwell et al., 1997) , cell death (Sowter et al., 2001) , sitivity, including apoptotic potential (Rupnow and Knox, 1999) , and metabolism (Firth et al., 1995; Semenza et al., 1994) . The mitotic potential (Denekamp, 1986) , and metabolic rate (Rojas importance of HIF-1 is underscored by its association with poor disease-specific outcomes for multiple cancer types (Bos and Denekamp, 1989) . These pleiotropic effects make it diffi- cult to predict whether a HIF-1-inhibiting strategy would have gene expression. The PCR product was cloned into a retroviral vector designed to generate tetracycline-inducible expression an overall positive or negative impact on tumor radiosensitivity. Therefore, we investigate here (1) how HIF-1 blockade influof the dominant-negative mutant in transduced HCT116 and PC-3 cells. ences tumor apoptosis, metabolism, proliferation, and angiogenesis, and (2) how each of these factors, in turn, affects raThese models were both very effective at inhibiting HIF-1. The level of HIF-1α knockdown achieved by siRNA in 4T1 cells diosensitivity. The results of these studies are then used to rationally design and test strategies for the optimal timing of was greater than 90% ( Figure 1C ). In HCT116 and PC-3 cells, the tetracycline-responsive dominant-negative HIF-1α con-HIF-1 blockade relative to radiotherapy. This work may be vital to the clinical development of HIF-1 inhibitors for use with struct was negligibly active in the absence of doxycycline, yet was a strong HIF-1 inhibitor in its presence ( Figure 1D ). Interother treatment modalities.
estingly, 4T1 cells responded less well to the dominant-negative construct as compared to the anti-HIF-1α siRNA, and the Results converse was true for HCT116 and PC-3 cells (data not shown). Therefore, we used siRNA exclusively for 4T1 cells, Establishing models of HIF-1 inhibition We first sought to establish high-specificity molecular models and our HIF-1α mutant exclusively for HCT116 and PC-3 cells of HIF-1 inhibition using RNA interference and directed protein in the experiments to follow. mutagenesis. Retroviral vectors were designed to generate constitutive expression of HIF-1α-targeting or scrambled siRNA HIF-1 potentiates radiation-induced apoptosis One way HIF-1 might impact tumor radiosensitivity is through in transduced 4T1 cells ( Figure 1A ). Also, a dominant-negative mutant was created from HIF-1α cDNA using site-directed mumodulating apoptosis. HIF-1 has been shown to affect apoptosis in several ways. It stimulates upregulation of the proapotagenesis ( Figure 1B ). "Stitching" PCR reactions were run on HIF-1α cDNA to mutate the 25th and 30th residues, which had ptotic BNIP3 (Guo et al., 2001 ) and can directly stabilize p53 (An et al., 1998) . There are also data to suggest that HIF-1 been previously identified as critical for DNA binding and downstream gene transcription (Michel et al., 2002) . Further, can exert an antiapoptotic influence under certain conditions (Akakura et al., 2001) . It is likely that the overall impact of HIF-1 the primers were designed to amplify the amino-terminal half of the protein only, eliminating from the product the oxygenon apoptosis is context dependent. With these factors in mind, we first used the p53 +/+ HCT116 dependent degradation motifs of the carboxy-terminal half of the protein. This resulted in a HIF-1α mutant with oxygen-indeline to examine how HIF-1 affects radiation-induced apoptosis. HCT116 cells were irradiated with or without first being expendent stability and an inability to upregulate downstream . HIF-1 is required for hypoxic potentiation of radiation damage A: Luminescent caspase 3/7 assay run on HCT116 cells 6 hr after treatment with 0 or 8 Gy of radiation. Cells were cultured for 24 hr under normoxia (21% O 2 ) or hypoxia (0.5% O 2 ) prior to irradiation. As with all experiments, hypoxic cells were reoxygenated for 10 min immediately before irradiation. Caspase activity was significantly enhanced after radiation for hypoxiastimulated cells, through a HIF-1-dependent mechanism (*p < 0.05 versus −dox). B: FACS analysis of DNA content in HCT116 cells 48 hr after receiving 8 Gy of radiation. Before irradiation, cells were stimulated by 24 hr of hypoxia and 10 min of reoxygenation. HIF-1 inhibition caused these cells to shift from apoptosis to G2/M arrest (*p < 0.05 versus −dox). S phase cells (data not shown) made up a very small percentage of the total population for both groups. C: HCT116 tumors, with or without HIF-1 inhibition, were removed 48 hr after (sham) irradiation (3 × 4 Gy). Sections were labeled by TUNEL staining, and the results were quantified by counting the number of positive nuclei per high-powered field. HIF-1 inhibition significantly suppressed apoptosis (*p < 0.05 versus −dox). n = 5/group. D: HCT116 cells were cultured for 24 hr under normoxia or hypoxia and in the presence or absence of doxycycline, reoxygenated briefly prior to irradiation, and assayed for clonogenicity 7 days after irradiation. Exposure to hypoxia before irradiation caused a significant left-shift in the survival curve (closed triangles; p < 0.05 versus 21% O 2 and −dox), and HIF-1 inhibition abrogated this response (open triangles). Errors bars represent the standard deviation of the mean.
posed to a 24 hr period of hypoxia to activate HIF-1. Since nuclei were significantly less common in HIF-1-inhibited HCT116 hypoxia lowers the relative efficacy of radiation (Berry et al., tumors, both at baseline and 48 hr after irradiation. 1970), hypoxic cells were reoxygenated 10 min prior to irradiaAlthough these data indicate that HIF-1 inhibition protects tion for this experiment as well as those to follow. This way, hypoxic cells from radiation-induced apoptosis, this may not our results vary strictly as a function of differential hypoxiacorrelate with an effect on clonogenicity (Abend, 2003) . From induced gene and protein regulation, not as a function of the a therapeutic standpoint, if the excess G2-arrested population oxygen enhancement effect on radiation damage.
shown in Figure 2B does not eventually recover and demonCaspase 3/7 activation and DNA fragmentation were used strate clonogenic capacity, the effect of HIF-1 blockade may to analyze the effects of radiation on early (6 hr) and late (48 be negligible. For this reason, clonogenic survival was deterhr) apoptosis, respectively. There was a significant difference mined for the HCT116 cells after radiation, with or without prein the early apoptotic response to radiation between cells that incubation under hypoxia, and with or without stimulation by had been cultured in normoxia and hypoxia before irradiation doxycycline ( Figure 2D ). Expressing the dominant-negative (hereafter referred to as "normoxic/irradiated" and "hypoxic/ mutant had no impact on clonogenicity of aerobic cells followirradiated," respectively). Whereas normoxic/irradiated cells ing irradiation. In cells exposed to hypoxia before irradiation, underwent only modest caspase activation at 6 hr, this reon the other hand, clonogenic survival was significantly ensponse was markedly enhanced in the hypoxic/irradiated hanced by HIF-1 blockade, with a 2-log-kill isoeffect dosegroup (Figure 2A ). This potentiation was completely absent in modifying factor (2L-DMF) of 1.22. cells expressing the dominant-negative mutant, proving this to be a HIF-1-dependent effect. DNA content analysis of these p53 is required for HIF-1-dependent apoptotic induction cells 48 hr after irradiation demonstrated that a large fraction Since it has been implicated previously in the link between of the hypoxic/irradiated group proceeded from caspase acti-HIF-1 and apoptosis, we next sought to determine whether vation to apoptosis (24.2% ± 0.5%), and that this fraction was p53 was required for the effects described above. HCT116 markedly lower (3.6% ± 0.1%) in HIF-1-inhibited cells ( Figure  cells were cultured for 24 hr under normoxia or hypoxia, in the 2B). The decrease in the fraction of apoptotic cells in the HIF-1-presence or absence of doxycycline stimulation, and briefly inhibited group was balanced by an increase in the G2/M popreoxygenated before irradiation. One hour after irradiation, ulation (59.3% ± 1.4% +dox versus 39.3% ± 0.1% −dox), sugnuclear extracts were prepared from these groups and run on gesting that the loss of HIF-1 shifts hypoxic/irradiated cells a Western blot ( Figure 3A ). Radiation and hypoxia both led to from apoptotic to G2-arrested fates.
increased p53 immunoreactivity in nuclear extracts, but comThe impact of HIF-1 inhibition on apoptosis was also examined for tumor cells grown in vivo ( Figure 2C ). TUNEL-positive bining the two stimuli did not further enhance this effect. Radi- A: Immunoblots of nuclear extracts prepared from HCT116 cells 1 hr after radiation. Cells were exposed to normoxia (21% O 2 ) or hypoxia (0.5% O 2 ) for 24 hr, in the presence or absence of doxycycline, before irradiation (8 Gy).
B:
Immunoblots of whole-cell extracts from PC-3 cells transduced with a p53 expression vector (p53) or control vector (VC). C: Caspase 3/7 assay run on p53-transduced PC-3 cells treated as in Figure 2A . Caspase activity was significantly enhanced in cells irradiated after hypoxic conditioning, in a HIF-1-dependent fashion (*p < 0.05 versus −dox). Error bars represent the standard deviation of the mean. D: Clonogenicity of p53-transduced PC-3 cells treated as in Figure 2D prior to irradiation (10 Gy). Pretreatment with hypoxia significantly radiosensitized these cells (p < 0.05 versus 21% O 2 and −dox), through a HIF-1-dependent mechanism. Error bars represent the standard deviation of the mean.
ation and hypoxia also both led to increased phospho-p53 reconstitution. However, caspase activity following hypoxia/ (serine 15) immunoreactivity, and combining the two stimuli irradiation was dramatically higher for the p53-expressing cells lead to further p53 phosphorylation. Importantly, hypoxia/radithan it was for p53 null PC-3 cells. Moreover, the caspase acation-induced p53 phosphorylation was abrogated by HIF-1 intivity enhancement for this group was abrogated when HIF-1 hibition. These data provide strong evidence, then, that HIF-1 was inhibited, as had been the case for the HCT116 cell line is required for enhancement of radiation-induced p53 activa-( Figure 3C ). DNA content analysis after 48 hr showed that the tion by hypoxia. They also suggest that p53 may be required p53-reconstituted PC-3 cells had a significant increase in the for HIF-1-mediated potentiation of radiation-induced apoptosis apoptotic population after hypoxia/irradiation (15.2% ± 0.4%), by hypoxia. which was effectively blocked by HIF-1 inhibition (0.8% ± To further investigate this latter hypothesis, we engineered a 0.4%). As was the case with the HCT116 line, the apoptotic paired cell line in the PC-3 background distinguished only by cell population was shifted to G2 arrest in HIF-1-inhibited cells p53 expression status. This was accomplished by transducing (data not shown). Finally, the impact of HIF-1 activity on the wild-type human p53 cDNA (a generous gift from V. Seewaldt) clonogenicity of hypoxic/irradiated cells was shown again here into the p53 null PC-3 cell line ( Figure 3B ). Taking advantage with p53-reconstituted PC-3 cells ( Figure 3D ). Once more, the of the inducible HIF-1α mutant already established in this line, clonogenicity of normoxic cells was not affected by HIF-1 we were then able to study the effects of hypoxia on radiationblockade. The radiosensitivity of hypoxic, HIF-1-inhibited cells induced apoptosis in the presence or absence of both HIF-1 was similar to that of the normoxic cells. Hypoxic cells with and p53 functionality. In native (p53 null) PC-3 cells, exposure intact HIF-1 function, on the other hand, were significantly less to hypoxia before radiation fails to augment subsequent casclonogenic following 10 Gy of radiation. pase 3/7 activation, DNA fragmentation, or loss of clonogenic To summarize, HIF-1 promotes p53 phosphorylation at sersurvival; accordingly, HIF-1 inhibition has no impact on these ine 15 in response to hypoxia and, more so, upon irradiation outcomes (see Figure S1 in the Supplemental Data available after hypoxic conditioning. As a consequence, HIF-1 and p53 with this article online). For p53-expressing PC-3 cells, howare both required for hypoxic potentiation of radiation-induced ever, the response is quite different. As would be predicted, caspase 3/7 activity was increased across the board after p53 caspase activation, apoptosis, and loss of clonogenicity.
HIF-1 maintains tumor energy metabolism cells becoming significantly more radioresistant (2L-DMF = 1.49), consistent with the lowered energy state of these cells. Recent work has provided strong evidence for the role of HIF-1 in regulating glucose metabolism and energy maintenance in
We also compared survival curves for HCT116 cells exposed to hypoxia and doxycycline, with or without glucose deprivation tumors (Griffiths et al., 2002) . Glucose levels and metabolic activity have been directly associated with tumor cell radiosensi-( Figure S2 ). Low glucose concentrations induced radioresistance in these cells to a degree similar to that seen for PC-3 tivity (Heller and Raaphorst, 1994; Luk and Sutherland, 1987) . Therefore, we sought to determine how HIF-1 inhibition would cells (2L-DMF = 1.31). In summary, HIF-1 maintains glucose metabolism and ATP alter energy metabolism in tumors, and how this effect might influence overall radiosensitivity.
production in tumor cells, most prominently in the center of tumors, sustaining bioenergetics at a level required for high We first examined how HIF-1 inhibition influences glucose consumption in our models. 4T1 and HCT116 cells were excellular sensitivity to radiation. posed to 24 hr of normoxia or hypoxia, with or without HIF-1 inhibition, and were subsequently assayed for glucose con-HIF-1 proliferation effects vary with microenvironment It has been reported that HIF-1 is required for cell cycle arrest sumption rates ( Figure 4A ). There was an enhancement of glucose consumption after exposure to hypoxia, and this effect in response to hypoxia (Goda et al., 2003) . Since cell cycle phase also influences radiosensitivity, we next sought to inveswas abrogated by HIF-1 blockade for both cell lines. We hypothesized that this impaired glucose utilization would lead to tigate whether HIF-1 inhibition might impact tumor radioresponsiveness through its effects on proliferation rate. decreased ATP production in HIF-1-inhibited cells. To test this hypothesis, 4T1 and HCT116 cells were stressed by hypoxia 4T1 and PC-3 cells were cultured for 24 hr in hypoxic or normoxic conditions, with high or low glucose concentrations for 24 hr, with or without glucose deprivation, with or without HIF-1 inhibition, and then assayed for total cellular ATP levels in the media. MTT assays showed that HIF-1-inhibited cells were more viable than controls after hypoxia alone, but less so ( Figure 4B ). Neither hypoxia nor glucose deprivation alone was sufficient to deplete cellular ATP, whether the cells were HIF-1 after combined hypoxia and glucose deprivation ( Figure 5A ). Analysis of DNA content revealed that cell cycle arrest was at inhibited or not (data not shown). When the two stressors were combined, however, ATP levels fell for both groups. Consistent least in part responsible for these effects ( Figure 5B ). HIF-1 inhibition attenuated G1 blockade following hypoxia alone, with their impaired ability to consume glucose, the HIF-1-inhibited cells experienced a significantly greater reduction in ATP consistent with its role in promoting hypoxic growth arrest. In contrast, the loss of HIF-1 promoted G1 arrest in response to stores after the combined stress.
Next, 4T1 and HCT116 tumors were grown in mice to detercombined oxygen and glucose deprivation.
To determine whether these results are relevant to the micromine whether HIF-1 inhibition would influence ATP levels in vivo ( Figure 4C ). Bioluminescence imaging was used to quanenvironment encountered by tumors in vivo, patterns of cellular proliferation were analyzed in tumor sections using Ki-67 tify ATP concentrations in frozen tissue sections (Schwickert et al., 1996) . HIF-1 blockade caused a 5-fold reduction in overall immunohistochemistry. There appeared to be qualitative differences between the groups in how proliferation indices varied ATP levels for 4T1 tumors, and a 2-fold reduction for HCT116 tumors. Spatially, the loss of ATP was most significant near the with the distance from perfused vasculature ( Figure 5C ). Quantitative analysis of these data revealed that there was, indeed, center of HIF-1-inhibited tumors, with levels at the periphery being similar to that found in wild-type tumors. Similarly, HIF-1 distinct variation in the spatial patterns of proliferation between the wild-type and HIF-1-inhibited groups ( Figure 5D ). For both blockade was also found to increase the area of central necrosis for both tumor types studied. The diameter of the viable rim groups, proliferation indices fell off significantly as distance from the vasculature increased (p < 0.05), as expected. There of tumor identified by H&E staining was significantly smaller in HIF-1-inhibited tumors (4T1, 0.92 ± 0.48 mm; HCT116, 1.32 ± was no significant effect of HIF-1 inhibition on the global proliferation indices for the groups (p > 0.05). However, there was a 0.63 mm) as compared to their controls (4T1, 4.94 ± 1.04 mm; HCT116, 3.29 ± 0.61 mm; p < 0.05; n = 5/group). highly significant interaction between group and distance (p < 0.001). HIF-1 knockdown tumors were more proliferative in tisThe above data indicate that HIF-1 inhibition impairs tumor energy metabolism, leading to a reduction in ATP levels and sues near vasculature (%240 m), whereas wild-type tumors were more proliferative in tissues far from vasculature (R240 cellular viability. As reduced metabolic rates have been linked with radioresistance, we next examined whether inhibiting HIF-1 m). To control for potential differences in nuclear density between the groups, a similar analysis was run on sections counin nutrient-depleted cells would influence clonogenic survival after irradiation. Wild-type PC-3 cells were chosen for this exterstained for total nuclei. In general, nuclear densities decreased with distance from perfused vasculature for both periment because hypoxia does not affect their clonogenicity after irradiation ( Figure S1) ; therefore, oxygenation could be groups, but there was no significant difference in nuclear density between the groups at any given distance (p > 0.05; data eliminated as a variable in the following experiment. PC-3 cells were cultured for 24 hr under hypoxia, in high or low glucose not shown).
We next examined whether HIF-1 influences radiosensitivity concentrations, with or without stimulation by doxycycline (Figure 4D) . As before, the cells were briefly reoxygenated prior to through regulating cellular proliferation rates. Wild-type PC-3 cells were again used here, as hypoxia does not affect their irradiation. HIF-1 blockade failed to affect clonogenic survival in cells exposed to high glucose concentrations prior to irradiaclonogenicity after radiation, eliminating oxygenation as an experimental variable. PC-3 cells were cultured under hypoxic tion. For cells cultured in low-glucose conditions, however, survival curves were significantly right shifted. Low glucose alone conditions for 24 hr, with or without doxycycline stimulation, and with or without aphidicolin-induced cell cycle synchronizainduced modest radioresistance in the PC-3 cells (2L-DMF = 1.14). Combining low glucose with HIF-1 blockade resulted in tion ( Figure 5E ). Next, the cells were briefly reoxygenated and then immediately irradiated. Aphidicolin, which causes G1/S HIF-1 promotes vessel radioresistance HIF-1-inhibiting compounds, delivered after radiation, lead to cell cycle arrest, resulted in a slight right-shift in the survival curve for hypoxic cells (2L-DMF = 1.14), likely through arresting significant destruction of tumor vasculature and prolonged time to tumor regrowth after therapy (Moeller et al., 2004) . Were those cells which had escaped HIF-1-mediated cell cycle blockade. It caused a significantly greater shift toward radiorethe sequence or timing of therapeutic delivery altered, however, it is unknown whether this approach would remain effecsistance when applied to HIF-1-inhibited, hypoxic cells (2L-DMF = 1.31), wherein a larger fraction of cells had escaped G1 tive. It is possible, for example, that preradiation HIF-1 blockade might have antiangiogenic effects on tumors (Stoeltzing et blockade secondary to HIF-1 dysfunction. Similar results were seen for HCT116 cells ( Figure S3 ). These data suggest that al., 2004). This could, conceivably, compromise radiotherapy by decreasing tumor oxygenation-an effect previously described HIF-1 normally acts to lower radiosensitivity in hypoxic cells by promoting cell cycle arrest. However, it also normally functions for another antiangiogenic therapy (Murata et al., 1997). Therefore, we next sought to investigate how HIF-1 blockade influto sustain mitotic rates for cells starved of both glucose and oxygen, likely leading to relative radiosensitization of these enced tumor vascularity in our models, and whether the timing of HIF-1 inhibition would affect its overall impact on tumor vescells. Therefore, the overall impact of HIF-1 activity on tumor radiosensitivity, due to its effects on proliferation, is likely desel radiosensitivity.
To begin, we first examined how HIF-1 blockade affects early pendent on the microenvironment. tumor angiogenesis. We elected against using our dominantThough it did not appear to alter baseline tumor vessel anatnegative model for this study, as we were concerned that tranomy or physiology, our prior work suggests that HIF-1 inhibisient HIF-1 activation, occurring before expression of the mution dramatically increases tumor vessel radiosensitivity. Theretant could be induced in vivo, could have dramatic effects on fore, we next sought to determine (1) whether our biological, angiogenesis. Therefore, we used our siRNA model for this high-specificity models of HIF-1 inhibition also radiosensitized study, measuring angiogenesis in 4T1 tumors by following their tumor vasculature, and (2) whether the timing of HIF-1 inhibivascularity over time using dorsal skinfold window chambers. tion with radiotherapy would impact this result. We used 4T1, Since HIF-1 blockade had no effect on overall 4T1 tumor HCT116, and PC-3 tumors, grown in the dorsal skinfold wingrowth rate (data not shown), we could compare vascularity dow chamber, to monitor changes in tumor vascularity over between groups over time without adjusting for tumor volume.
time following HIF-1 blockade and radiotherapy. 4T1 knockThere was a delay in initial tumor vascularization in the HIF-1-down tumors underwent significant vascular regression followinhibited tumor group, most pronounced at day 10 following ing irradiation, whereas control tumor vessel density trended tumor cell inoculation ( Figure 6A ). After that point, however, higher ( Figure 6B ). Next, pre-and postradiation doxycycline there were no significant differences in vascular density betreatments were tested on HCT116 and PC-3 window chamber tween the two treatment groups. Next, immunohistochemistry tumors to determine whether these sequences would cause was used to determine whether this parity in angiogenesis held differential vascular radiosensitization. Each combination infor larger tumors (volume, 1000 mm 3 ; n = 5/group). Vascular duced significant tumor devascularization as compared to radidensity, vessel maturity, and tumor oxygenation were all similar ation alone, with neither sequence being more effective at dofor both control and knockdown tumors (see the Supplemental Data).
ing so than the other ( Figure 6C ). Therefore, HIF-1 blockade is an effective means of enhancing radiation damage to tumor blockade, on the other hand, have been shown here to cause vasculature, irrespective of treatment sequencing. radiosensitization regardless of sequencing with radiation ( Figure 6) ; therefore, this mechanism could significantly influence treatment outcome whether modified before or after radiother-HIF-1 blockade is maximally effective following radiation Results from the above experiments suggest that HIF-1 influapy. Based on this reasoning, it was hypothesized that postradiation HIF-1 blockade would have significantly greater antituences tumor cell radiosensitivity through multiple mechanisms. By promoting apoptosis, metabolism, and proliferation of nutrimor effects than would preradiation HIF-1 inhibition.
To test this hypothesis, HCT116 and PC-3 tumors were ranent-starved cells, HIF-1 enhances tumor radiosensitivity. In contrast, HIF-1 also dramatically decreases tumor radiosensidomized to the treatment groups outlined in Figure 7A , and the corresponding growth delay data are displayed in Figures 7B tivity through cytokine-mediated protection of tumor vasculature. Importantly, the time course over which these opposing and 7C. Average tumor volumes among the various treatment groups for each tumor line were not significantly different at the mechanisms occur is likely distinct, raising the possibility that the proper timing of HIF-1 blockade could optimize its effects times of randomization (1 week postimplantation) or irradiation (2 weeks postimplantation). Subsequent growth rates were not on radiotherapy. Specifically, the effects of HIF-1 inhibition on apoptosis, metabolism, and proliferation would be expected to affected by HIF-1 inhibition alone. Combining HIF-1 blockade with radiation, however, significantly enhanced tumor growth influence the immediate response of tumors to ionizing damage; therefore, these mechanisms may not significantly infludelay. For HCT116 tumors, the efficacy of this approach was highly dependent on sequencing. Preradiation HIF-1 blockade ence treatment outcome unless modified before radiation is delivered. Consistent with this hypothesis, we found that postextended the time to reach 5× initial treatment volume by approximately 3 days (p < 0.05 versus radiotherapy [RT] alone). radiation HIF-1 blockade failed to modify tumor cell clonogenicity in situations where preradiation HIF-1 inhibition had sucPostradiation HIF-1 inhibition extended the same interval by 15 days (p < 0.001 versus RT alone). By this metric, the "radiation ceeded in doing so ( Figure S4 ). The vascular effects of HIF-1 but the magnitude of the sequencing effect may vary from tumor to tumor.
Discussion
The idea that HIF-1 may be a good target for cancer therapy is not a new one (Giaccia et al., 2003; . HIF-1 is active in virtually all tumors, and it plays key roles in promoting malignant behavior. Moreover, some preclinical studies on xenograft tumors have shown that HIF-1 inhibition slows tumor growth (Kung et al., 2000) , while its activation accelerates growth (Ravi et al., 2000) . Though these data establish the rationale for using HIF-1 blockade as a single-modality cancer therapy, work done previously by our group suggests that HIF-1 blockade will work best when combined with other treatments such as radiotherapy.
However, as discussed above, HIF-1 may also serve to radiosensitize tumors through various mechanisms. Indeed, we have demonstrated here that HIF-1 can enhance tumor radiosensitivity through increasing apoptotic potential, proliferation rates, and ATP metabolism. Because the importance of these effects varies with the tumor microenvironment and target cell type, the impact of HIF-1 inhibition is also likely to differ depending on location within the tumor (Table 1) . HIF-1 blockade has pronounced radiosensitizing effects on tumor vasculature, seemingly irrespective of vessel location. The impact of HIF-1 inhibition on radiosensitivity of tumor cells, on the other hand, probably depends strongly on the local physiological microenvironment. For well-oxygenated tumor cells, HIF-1 is unlikely to be active, and its inhibition is probably not consequential. For hypoxic cells with sufficient access to glycolytic energy stores, HIF-1 inhibition will increase proliferation rates by abrogating G1 blockade mechanisms while decreasing apoptotic potential by suppressing p53 activation-the balance of these mor cells-equally affected by HIF-1 inhibition, the ultimate imTumor regrowth after treatment was significantly delayed for all irradiated groups (p < 0.05 versus NT). Preradiation doxycycline treatment caused a pact on radiosensitivity would depend on which is the more significantly prolonged growth delay (p < 0.05 versus RT) for both tumor important determinant of radiation outcome. A strong case has types. Postradiation doxycycline treatment caused a marked enhancerecently been made for the importance of tumor vasculature ment in growth delay, significantly greater than that for both of the other in determining radiosensitivity (Garcia-Barros et al., 2003) . An irradiated groups (p < 0.05). The difference in efficacy between the two sequencing schema was much more pronounced for HCT116 tumors as equally compelling argument could be made for the impor- are initially protected from radiation damage by their microenvironment. As tumors reoxygenate and reperfuse during fractionated radiotherapy, they can overcome their prior growth restrictions and contribute to treatment failure. Therefore, it is first" strategy extended tumor growth delay for HCT116 tumors conceivable that both of these compartments, with radiosensifive times further than did the alternative sequencing. For PC-3 tivities highly dependent on HIF-1 activity, could contribute tumors, the difference in efficacy between the two sequencstrongly to overall tumor radioresponsiveness. ing strategies was much less pronounced. Preradiation HIF-1
If one hopes to optimize the combination of HIF-1-inhibiting blockade caused significant growth delay (p < 0.05 versus RT and cytotoxic therapies, then, the strategy used should aim to alone), extending the time to reach 5× initial treatment volume maximize the effects of HIF-1 blockade on the vasculature by approximately 8 days. Postradiation HIF-1 inhibition also while minimizing effects on the distal tumor cells. This could be significantly prolonged the growth delay (p < 0.05 versus RT achieved either through spatial or temporal selectivity of HIF-1 alone) and extended the 5× regrowth time by approximately 10 blockade. Since tumor vasculature is most influenced by cydays. Therefore, the efficacy of combined radiotherapy and tokine secretion from nearby ("proximal") tumor cells, spatial targeting of HIF-1 inhibition to the vasculature could be accom-HIF-1 inhibition is dependent on the sequencing of treatments, 
HIF-1 inhibition either increases ([), decreases (Y), or has no effect on (4) tumor and endothelial cell apoptosis, metabolism, and proliferation; the sum total of these effects determines how it influences radiosensitivity. "Proximal tumor" refers to tumor cells near perfused vasculature that are hypoxic but supplied with nutrients; "distal tumor" refers to tumor cells far from perfused vasculature that are both hypoxic and nutrient depleted.
plished by delivering the inhibitory agent via macromolecular 2000), but to our knowledge, they have never before been used carriers that penetrate only as far as these cells are located.
solely in already-established tumors as was done here. Since An alternative, somewhat simpler approach would be to target our approach seems more clinically relevant, we think it dethe effects of HIF-1 blockade to tumor vasculature through serves careful consideration. In contrast, our model of constispecific timing of therapeutic delivery, as was done here. The tutive HIF-1 blockade also failed to show tumor growth restricwindow of opportunity for radiosensitizing tumor vessels with tion. To our knowledge, no prior studies have used siRNA to HIF-1 inhibition was large, since the sequencing of treatments inhibit HIF-1α activity in vivo-the discrepancy here may, therewas irrelevant. The therapeutic window for changing tumor cell fore, be methodological. Future work will need to be done to radiosensitivity with HIF-1 blockade is narrower, as demonclarify whether HIF-1 inhibition by itself is an effective anticanstrated above. Since HIF-1 mainly modulates processes that cer tool. influence the immediate response to ionizing radiation damage This work may have important implications for the way in in tumor cells, HIF-1 must be inhibited prior to irradiation to which HIF-1 inhibitors are used in the clinic. Our data suggest have an effect in this compartment. Therefore, "radiation first"
that HIF-1 blockade will be suboptimally effective if used prior sequencing maximizes the efficacy of combining HIF-1 blockto cytotoxic therapy. Although this sequencing may be a suitade with cytotoxic therapy by preferentially exploiting the antiable approach for other antiangiogenic agents (Winkler et al., vascular component of this strategy.
2004), HIF-1 inhibitors might impede therapy if used this way. Due to promising preclinical trials, there is much interest in
As an alternative, we propose that HIF-1 blockade should be developing new targeted therapy strategies for radiosensitizing used concurrently with chemotherapy and/or radiotherapy. tumor vasculature. We feel that HIF-1 should be a leading canOne way to do so would be to administer HIF-1 blockade didate among those proposed so far. Because it targets signalthroughout the course of chemotherapy/radiotherapy, thereby ing pathways that promote vascular radioresistance in tumors, maximally sensitizing the tumor vasculature. Alternatively, one but not in normal tissues, HIF-1 blockade is a tumor-specific could inhibit HIF-1 during breaks from treatment (e.g., over the approach to this problem. By targeting multiple nonoverlapping weekend for fractionated radiotherapy or between cycles of vascular-protecting pathways at their upstream source, HIF-1 chemotherapy), thereby minimizing the potential for interfering blockade is also a potent multifaceted approach to this probwith their cytotoxicity. lem. Moreover, the data presented here may underestimate the It is also important to note that patient selection may play an efficacy of this approach. Our model studied the effects of HIF-1 eventual role in maximizing the potency of HIF-1 blockade. The inhibition on tumor cells only, but its effects on stromal cells mechanisms of radiation-induced HIF-1 activation are depenmay be highly significant as well. It has recently been reported dent on the presence of tumor hypoxia before treatment that HIF-1 activity is important within tumor endothelial cells (Moeller et al., 2004) . Therefore, methods of identifying tumors themselves, wherein it serves to fuel an autocrine VEGF loop with high hypoxic fractions could be useful in selecting patients that maintains angiogenesis and vascularity (Tang et al., 2004) . who will benefit from HIF-1 blockade during chemo/radiotherSince VEGF is a key promoter of endothelial radioresistance apy. Similarly, tumors found to have high HIF-1α expression (Gorski et al., 1999) , HIF-1 inhibition within tumor endothelial levels may respond best to this type of treatment. There is alcells may increase overall tumor radiosensitivity beyond the ready a large body of work demonstrating that HIF-1α expreslevels seen here. Such a mechanism might counterbalance the sion correlates with poor clinical outcome (Semenza, 2002) . If protective effects of HIF-1 blockade for p53-expressing tuthis at-risk population could be identified and offered HIF-1 mors, rendering the overall effect beneficial irrespective of the blockade as adjunctive therapy, they might benefit greatly. It tumor cell radioprotection. This possibility certainly warrants was also shown here that p53 status is a major determinant of further investigation.
how HIF-1 affects tumor radiosensitivity. As a result, it may also Further underscoring the importance of coupling HIF-1 inhibe beneficial to use HIF-1 inhibition preferentially for tumors bition with radiation, our studies suggest that HIF-1 blockade with documented p53 mutations, as they will be less sensitive may be an ineffective single-modality therapy. Several prior to its radioresistance-inducing effects. Interestingly, clinical studies have reported tumor growth inhibition after HIF-1 studies have previously shown that the finding of nonfunctional blockade. However, many of these experiments used fibrop53 and high levels of HIF-1α portends a particularly poor blasts or stem cells derived from HIF-1α knockout mice inprognosis (Birner et al., 2001 ). The combined HIF-1 blockade/ stead of established tumor lines (Carmeliet et al., 1998; Ryan radiotherapy regimen described above may be highly effective et al., 1998). HIF-1α mutant proteins have been used in the past to successfully reduce tumor growth rates (Kung et al., for this difficult-to-treat tumor population, suggesting again
Supplemental data
that patient selection may be critical to optimizing this therapeutic option. These issues warrant further study. 
